1. Methodological quality of included studies.
Study ID | No. patients | Placebo RCT | Allocation blinded | Recipients blinded | Outcome blinded | Loss of follow‐up | Multi‐centre | Risk of bias |
Appleton 1999 | 40 | yes | yes | yes | yes | no | yes | low |
Askalan 2003 | 9 | no | not clear | no | some | no | no | high |
Baram 1996 | 29 | no | yes | no | yes | none | no | high |
Chiron 1997 | 22 | no | not clear | no | no | none | yes | high |
Debus 2004 | 51 | yes | yes | yes | no | no | yes | low |
Dreifuss 1986 | 52 | no | not clear | no | yes | yes | yes | high |
Dyken 1985 | 17 | yes | not clear | yes | yes | yes | no | high |
Elterman 2010 | 221 | no | not clear | no | no | yes | yes | high |
Hrachovy 1983 | 24 | no | not clear | yes | not clear | none | unclear | high |
Hrachovy 1989 | 24 | no | not clear | not clear | not clear | none | unclear | high |
Hrachovy 1994 | 59 | no | not clear | no | yes | yes | unclear | high |
Lux 2004 | 107 | no | yes | no | no except developmental outcome | yes | yes | high |
Bitton 2012 | 68 | yes | not clear | yes | yes | yes | yes | low |
Shu 2009 | 30 | no | not clear | not clear | not clear | not clear | not clear | high |
Tsai 2009 | 56 | yes | not clear | yes | yes | not clear | not clear | high |
Vigevano 1997 | 42 | no | not clear | no | not clear | none | no | high |
Yanagaki 1999 | 26 | no | not clear | not clear | not clear | yes | no | high |
Zou 2010 | 38 | no | not clear | no | no | no | no | unclear |